Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: Explorative analyses from the PREMIER study

Annals of the Rheumatic Diseases

Volumn 68, Issue 7, 2009, Pages 1171-1176

  Hoff, M ^a   Kvien, T K ^b,c   Kalvesten J ^d   Elden, A ^e   Haugeberg, G ^a,f  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d Sectra Imtec   (Sweden)

^e ABBOTT LABORATORIES   (United States)

^f SØRLANDET HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; METHOTREXATE; PLACEBO; PREDNISOLONE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; FEMALE; HAND BONE; HUMAN; MAJOR CLINICAL STUDY; MALE; METACARPAL BONE; MONOTHERAPY; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME; X RAY; BONE DENSITY; METABOLIC BONE DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY;

ABSORPTIOMETRY, PHOTON; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE DISEASES, METABOLIC; DOUBLE-BLIND METHOD; FEMALE; HAND BONES; HUMANS; MALE; MIDDLE AGED;

EID: 67549150896     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.091264     Document Type: Article

References (40)

1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, et al. Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 2006;65:736-40.
3. Devlin J, Lilley J, Gough A, Huissoon A, Holder R, Reece R, et al. Clinical associations of dual-energy X-ray absorptiometry measurement of hand bone mass in rheumatoid arthritis. Br J Rheumatol 1996;35:1256-62.
4. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, et al. Changes in hand and generalized bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. Published Online First 14 July 2008. doi:10.1136/ard.2007.086348.
5. Hoff M, Haugeberg G, Odegard S, Syversen S, Landewe R, van der Heijde D, et al. Cortical hand bone loss after one year in early rheumatoid arthritis predicts radiographic hand joint damage at 5 and 10 year follow-up. Ann Rheum Dis. Published Online First 13 March 2008. doi:10.1136/ard.2007.085985.
6. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
7. Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O'Connor PJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006;54:1410-14.
8. Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin North Am 2006; 32:759-73.
9. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
10. van der Heijde DM, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
11. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
12. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007;9:R61.
13. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005;44:1546-8.
14. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van der Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1495-9.
15. Haugeberg G, Green MJ, Conaghan PG, Quinn M, Wakefield R, Proudman SM, et al. Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 2007;66:1513-17.
16. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006;1069:420-7.
17. Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebocontrolled trial. Arch Intern Med 2005;165:1293- 7.
18. Barnett E, Nordin BE. The radiological diagnosis of osteoporosis: a new approach. Clin Radiol 1960;11:166-74.
19. Rosholm A, Hyldstrup L, Backsgaard L, Grunkin M, Thodberg HH. Estimation of bone mineral density by digital X-ray radiogrammetry: theoretical background and clinical testing. Osteoporos Int 2001;12:961-9.
20. Jorgensen JT, Andersen PB, Rosholm A, Bjarnason NH. Digital X-ray radiogrammetry: a new appendicular bone densitometric method with high precision. Clin Physiol 2000;20:330-5.
21. Hyldstrup L, Nielsen SP. Metacarpal index by digital X-ray radiogrammetry: normative reference values and comparison with dual X-ray absorptiometry. J Clin Densitom 2001;4:299-306.
22. Nielsen SP. The metacarpal index revisited: a brief overview. J Clin Densitom 2001;4:199-207.
23. Hoff M, Dhainaut A, Kvien TK, Haugeberg G. Short time precision assessed with digital X-ray radiogrammetry in healthy individuals and rheumatoid arthritis patients [abstract.] Ann Rheum Dis 2008;67(suppl 2):563.
24. Bottcher J, Malich A, Pfeil A, Petrovitch A, Lehmann G, Heyne JP, et al. Potential clinical relevance of digital radiogrammetry for quantification of periarticular bone demineralization in patients suffering from rheumatoid arthritis depending on severity and compared with DXA. Eur Radiol 2004;14:631-7.
25. Hoff M, Haugeberg G, Kvien TK. Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss. Arthritis Res Ther 2007;9:R81.
26. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
27. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
28. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27.
29. Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984;11:13-16.
30. Xian CJ, Cool JC, Scherer MA, Macsai CE, Fan C, Covino M, et al. Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 2007;41:842-50.
31. di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola Gmuratore M, et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 2004;31:1305-9.
32. Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, et al. The effect of low dose methotrexate on bone density. J Rheumatol 2001;28:2395-9.
33. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002;41:741-9.
34. Emery P. The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol 1997;24:1436-42.
35. Dohn UM, Ejbjerg BJ, Court-Payen, Hasselquist M, Narvestad E, Szkularek M, et al. Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther 2006;8:R110.
36. Ostergaard M, Hansen M, Stoltenberg M, Jensen KE, Szkudlarek M, Pedersen-Zbinden B, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 2003;48:2128-31.
37. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54:3761-73.
38. Bottcher J, Pfeil A, Schafer ML, Petrovitch A, Seidl BE, Mentzel HJ, et al. Normative data for digital X-ray radiogrammetry from a female and male German cohort. J Clin Densitom 2006;9:341-50.
39. Toledo VA, Jergas M. Age-related changes in cortical bone mass: data from a German female cohort. Eur Radiol 2006;16:811-17.
40. Herrak P, Gortz B, Hayer S, Redlich K, Reiter E, Gasser J, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004;50:2327- 37.